ABBOTT LABORATORIES acquires BASF's pharmaceutical business (Knoll)
Snapshot
ABBOTT LABORATORIES acquired BASF's pharmaceutical business (Knoll) for approximately $6.9 billion in cash in March 2001. The transaction was structured as all cash. BASF's pharmaceutical business (Knoll) is a Ludwigshafen, Germany (global operations)-based Pharmaceuticals business.
- Acquirer
- ABBOTT LABORATORIES
- Target
- BASF's pharmaceutical business (Knoll)
- Value
- approximately $6.9 billion in cash
- Date
- March 2001
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
ABBOTT LABORATORIES acquired BASF's pharmaceutical business (Knoll) for approximately $6.9 billion in cash, a transaction completed in March 2001, structured as all cash.
BASF's pharmaceutical business (Knoll) operates in Pharmaceuticals, is based in Ludwigshafen, Germany (global operations). BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA).
Expanded Abbott's global pharmaceutical operations and added a research pipeline that included the antibody Abbott later developed into HUMIRA.
Global pharmaceutical scale plus a pipeline antibody that became one of the best-selling drugs in history. Integrated into Abbott's pharmaceutical business
No advisory firms have been disclosed for this transaction.